| scholarly article | Q13442814 |
| P50 | author | Massimo Broggini | Q58377329 |
| P2093 | author name string | Kanaga Sabapathy | |
| Faina Vikhanskaya | |||
| Marco Mazzoletti | |||
| Ming Kei Lee | |||
| P2860 | cites work | Mdm2 promotes the rapid degradation of p53 | Q24322597 |
| Mutant p53 proteins bind DNA in a DNA structure-selective mode | Q24791476 | ||
| Regulation of p53 stability by Mdm2 | Q27860744 | ||
| A system for stable expression of short interfering RNAs in mammalian cells | Q27860875 | ||
| Surfing the p53 network | Q28032484 | ||
| A common polymorphism acts as an intragenic modifier of mutant p53 behaviour | Q28118809 | ||
| Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants | Q28143345 | ||
| p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y | Q28213515 | ||
| Live or let die: the cell's response to p53 | Q29547663 | ||
| p300/CBP proteins: HATs for transcriptional bridges and scaffolds | Q29617981 | ||
| Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Q31041084 | ||
| Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators | Q33737277 | ||
| Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. | Q33931140 | ||
| Small molecules that reactivate mutant p53. | Q35204556 | ||
| Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. | Q35207550 | ||
| TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer | Q35727380 | ||
| Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues | Q38293690 | ||
| Relief of p53-mediated telomerase suppression by p73. | Q38330053 | ||
| Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: Relationship to vascular invasion and estrogen receptor-alpha | Q38517564 | ||
| Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain | Q39575066 | ||
| Trp53-dependent DNA-repair is affected by the codon 72 polymorphism | Q40319779 | ||
| Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors | Q40384723 | ||
| Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs | Q40408834 | ||
| Modulation of gene expression by tumor-derived p53 mutants | Q40502644 | ||
| Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. | Q40568020 | ||
| Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. | Q40788757 | ||
| Role for the p53 homologue p73 in E2F-1-induced apoptosis | Q40848736 | ||
| Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells | Q43844076 | ||
| Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins | Q44010460 | ||
| p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis | Q44426545 | ||
| Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression | Q46709821 | ||
| DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. | Q50320380 | ||
| Mutations truncating the EP300 acetylase in human cancers | Q57888722 | ||
| Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73 | Q58073315 | ||
| Ectopic mTERT expression in mouse embryonic stem cells does not affect differentiation but confers resistance to differentiation- and stress-induced p53-dependent apoptosis | Q61872130 | ||
| Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells | Q73155202 | ||
| Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants | Q73876727 | ||
| Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s | Q81553323 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2093-2104 | |
| P577 | publication date | 2007-03-07 | |
| P1433 | published in | Nucleic Acids Research | Q135122 |
| P1476 | title | Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53 | |
| P478 | volume | 35 |
| Q36905671 | Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities |
| Q37294632 | Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter |
| Q36306105 | Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis |
| Q35397889 | Apoptosis in cancer: from pathogenesis to treatment |
| Q52808195 | CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancer. |
| Q91045399 | Cancer therapeutic targeting using mutant-p53-specific siRNAs |
| Q64119694 | Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer |
| Q48761873 | Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma |
| Q38112074 | Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme |
| Q39890321 | DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells |
| Q37407604 | Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage |
| Q90061909 | Djulis (Chenopodium Formosanum) Prevents Colon Carcinogenesis via Regulating Antioxidative and Apoptotic Pathways in Rats |
| Q28077156 | Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness |
| Q35251779 | Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. |
| Q39134087 | Exploiting the p53 Pathway for Therapy. |
| Q50197086 | Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck |
| Q41880322 | GADD45A expression is correlated with patient prognosis in esophageal cancer |
| Q53741376 | GUARDIN is a p53-responsive long non-coding RNA that is essential for genomic stability. |
| Q42545893 | Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. |
| Q52707747 | HDAC inhibitors show differential epigenetic regulation and cell survival strategies on p53 mutant colon cancer cells. |
| Q39178533 | Heat-shock factor 1 both positively and negatively affects cellular clonogenic growth depending on p53 status. |
| Q37605827 | Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations. |
| Q89967079 | Heterozygous p53-R280T Mutation Enhances the Oncogenicity of NPC Cells Through Activating PI3K-Akt Signaling Pathway |
| Q47136872 | Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53. |
| Q36390683 | Histone modifications affect differential regulation of TGFβ- induced NADPH oxidase 4 (NOX4) by wild-type and mutant p53. |
| Q28237971 | IGF binding proteins in cancer: mechanistic and clinical insights |
| Q92912365 | ISG15 Deficiency Enhances HIV-1 Infection by Accumulating Misfolded p53 |
| Q39905546 | Id-1 activates Akt-mediated Wnt signaling and p27(Kip1) phosphorylation through PTEN inhibition |
| Q97538360 | Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer |
| Q39499342 | Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. |
| Q36413546 | Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage |
| Q34120722 | Involvement of p53 mutation and mismatch repair proteins dysregulation in NNK-induced malignant transformation of human bronchial epithelial cells |
| Q42600588 | Involvement of the insulin-like growth factor binding proteins in the cancer cell response to DNA damage |
| Q33914111 | KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling |
| Q35903564 | Mitochondrial dysfunction in cancer |
| Q33687048 | Mutant p53 gain-of-function in cancer |
| Q38197826 | Mutant p53 in cancer: new functions and therapeutic opportunities |
| Q92890190 | Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer |
| Q28080513 | Nuclear actions of insulin-like growth factor binding protein-3 |
| Q36462969 | Overexpression of p53 activated by small activating RNA suppresses the growth of human prostate cancer cells |
| Q42921293 | PTENtumor suppressor plays less prognostic role thanP53tumor suppressor in diffuse large B-cell lymphoma |
| Q98199317 | Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma |
| Q34651573 | Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells. |
| Q37323033 | SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1. |
| Q38751430 | Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status |
| Q36591517 | Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells |
| Q36309603 | Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival. |
| Q36728287 | Targeted p53 activation by saRNA suppresses human bladder cancer cells growth and metastasis |
| Q37138538 | Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells |
| Q26772237 | The Contrived Mutant p53 Oncogene - Beyond Loss of Functions |
| Q37220014 | The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis |
| Q26747452 | The Modulation of Apoptotic Pathways by Gammaherpesviruses |
| Q52719672 | The Relationship between TP53 Gene Status and Carboxylesterase 2 Expression in Human Colorectal Cancer. |
| Q57162865 | The p53 Pathway in Glioblastoma |
| Q35681952 | The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer |
| Q89460168 | The role of TP53 gain-of-function mutation in multifocal glioblastoma |
| Q47742599 | Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others |
| Q39036579 | Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis. |
| Q39005896 | Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. |
| Q35086367 | Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance |
| Q37582777 | When mutants gain new powers: news from the mutant p53 field. |
| Q24306453 | p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma |
| Q45888635 | p53: balancing tumour suppression and implications for the clinic |
| Q39121067 | p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells |
Search more.